ARCHIVES

Phase III Trial Data: Lenvatinib Extends PFS by Over 14 Months

This article is from The Cancer Letter archive.

Vol. 37 No. 6 | June 27, 2014

Download PDF Visit The Full Archive

Related Articles

‘We Cannot Tolerate One Third Reduction In Centers. Prevention, Clinical Trials Programs’

September 20, 1991

ASCO Proposes Two IOM Workshops On Changing Clinical Trials Group System

September 17, 2010

UCLA Forms Environmental Genomics Program

March 14, 2003

ACS Cancer Response System Budget Request Total $185,140

August 9, 1985

MSK, Fox Chase Volunteer to Limit Their Core Grants To Let Others Grow

June 29, 1990

Senate Legislation Tackles Drug Shortages, Proposes Faster Approval For “Breakthroughs”

April 27, 2012